Halozyme Therapeutics, INC Form 4 insider transactions

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports multiple transactions involving common stock, including option exercises and sales, under a pre-arranged Rule 10b5-1 trading plan.

Nicole LaBrosse, CFO of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Nicole LaBrosse, CFO of Halozyme Therapeutics, executed stock options and sold shares between June 26 and June 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised stock options and sold shares according to a pre-arranged Rule 10b5-1 trading plan.

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, was granted 20,137 restricted stock units (RSUs) in recognition of his contribution to a European patent issuance.

Director Matthew L. Posard sold 20,000 shares of Halozyme Therapeutics, Inc. (HALO) in two transactions on June 11 and June 12, 2024.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Matthew L. Posard reports the acquisition of restricted stock units and stock options in Halozyme Therapeutics, Inc.

Director Akiko Moni Miyashita reports acquisition of Halozyme Therapeutics stock and options as part of the director compensation program.

Director Connie Matsui reports acquisition of stock and option awards from Halozyme Therapeutics.

Director Krishnan Mahesh reported acquiring shares and options in Halozyme Therapeutics as part of the director compensation program.

Director Jeffrey William Henderson acquired shares and options in Halozyme Therapeutics as part of the company's director compensation program.

Director Barbara Gayle Duncan received 6,501 restricted stock units and an option to purchase 8,804 shares of common stock from Halozyme Therapeutics on April 25, 2024, as part of the company's director compensation program.

Director Bernadette Connaughton reports the acquisition of restricted stock units and stock options in Halozyme Therapeutics as part of the director compensation program.

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, exercised stock options to acquire a total of 11,618 shares of common stock on March 26, 2024.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports the sale and exercise of common stock options under a pre-arranged Rule 10b5-1 trading plan.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

Mark Howard Snyder, SVP and General Counsel of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

Nicole LaBrosse, CFO of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

CEO Helen Torley reports the acquisition of stock options and restricted stock units in Halozyme Therapeutics.